Skip to content
AnalystLens

Tenet Healthcare 8-K Report, Material Agreement (Nov 5, 2025)

Reports
Material Agreements·Financial Events·Exhibits & Filings
Filing Date
Filed November 5, 2025
Period End
November 4, 2025
Security
THC
In the record · 2016–202610-K1110-Q338-K176

THC filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 176 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jan ’19Jan ’19
  2. Deal closed8-K · Dec ’20Dec ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Material agreement8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.

On November 4, 2025, Tenet Healthcare Corporation entered into a new senior secured revolving Credit Agreement (the "ABL Agreement") with JPMorgan Chase Bank, N.A. as administrative agent, providing for revolving loans of up to $1.9 billiona with a $200 million sub-facility for letters of credit.

Borrowing availability is calculated by reference to a borrowing base tied to specified percentages of eligible accounts receivable, eligible inventory and Medicaid supplemental payments. Tenet's obligations are guaranteed by certain domestic wholly-owned hospital subsidiaries and secured by a first-priority lien on the accounts receivable and inventory of Tenet and those subsidiaries. The facility matures on November 4, 2030, subject to earlier springing maturities tied to certain senior notes due 2028 and senior secured notes due 2027 through 2030 if their principal exceeds $2.5 billionb and certain conditions are not met.

Also on the Closing Date, Tenet entered into Amendment No. 7 to its existing Letter of Credit Facility Agreement dated March 7, 2014, with Barclays Bank PLC as administrative agent. The amendment extends the scheduled maturity of the $200 millionc LC facility from March 16, 2027 to November 4, 2030. Pricing terms include a 0.25% per annum margin on unreimbursed drawings, an initial 0.25% unused commitment fee, and a 1.25% per annum fee on issued but undrawn letters of credit.

The filing also reports that the ABL agent and certain lenders and LC participants and their affiliates have provided and may continue to provide commercial banking, investment banking, underwriting and other financial advisory services to Tenet and its subsidiaries for customary fees. The full agreements are filed as Exhibits 10.1 and 10.2, with certain schedules omitted under Item 601(a)(5) of Regulation S-K.

02—Key points

Key Highlights

  1. New $1.9 billion senior secured ABL revolving credit facility entered November 4, 2025, maturing November 4, 2030, with JPMorgan Chase Bank, N.A. as administrative agent.
  2. Availability is governed by a borrowing base tied to eligible accounts receivable, eligible inventory and Medicaid supplemental payments.
  3. Facility is guaranteed by certain domestic wholly-owned hospital subsidiaries and secured by a first-priority lien on accounts receivable and inventory.
  4. Springing maturity provisions could accelerate the facility's termination 45 business days before maturities of certain 2027–2030 senior secured notes or 2028 senior notes, if principal exceeds $2.5 billion and specified conditions are not met.
  5. Revolving loan pricing is base rate plus 0.25% to 0.50% or SOFR/EURIBOR plus 1.25% to 1.50%, based on average quarterly available credit; undrawn commitments carry a 0.25% per annum commitment fee.
  6. Amendment No. 7 extends the $200 million letter of credit facility with Barclays Bank PLC from March 16, 2027 to November 4, 2030.
  7. Filing is also disclosed under Item 2.03 as a direct financial obligation created by the new agreements.

03—Questions

Frequently Asked Questions

  1. What is the size and term of Tenet Healthcare's new credit facility?

    Tenet entered into a senior secured revolving ABL Agreement providing up to $1.9 billion in revolving loans, with a $200 million sub-facility for letters of credit. The Scheduled Maturity Date is November 4, 2030, subject to springing maturity provisions.

  2. What collateral and guarantees support the ABL facility?

    Tenet's obligations are guaranteed by certain domestic wholly-owned hospital subsidiaries, and Tenet and those subsidiaries grant a first-priority lien on their accounts receivable and inventory.

  3. What are the springing maturity risks?

    The facility terminates 45 business days before the maturity of certain senior notes due 2028 or senior secured notes due 2027, 2028, 2029 or 2030 if the principal of that series exceeds $2.5 billion, unless at least 80% of the series is extended to at least one year after the Scheduled Maturity Date or repaid, defeased, discharged or refinanced, or the Excess Availability Condition is satisfied on a pro forma basis.

  4. How does the letter of credit facility change?

    Amendment No. 7 with Barclays Bank PLC extends the $200 million LC facility's scheduled maturity from March 16, 2027 to November 4, 2030, and sets a 0.25% per annum margin on unreimbursed drawings, an initial 0.25% unused commitment fee, and a 1.25% per annum fee on issued but undrawn letters of credit.

  5. Are the agreements publicly available in full?

    The ABL Agreement and LC Amendment are filed as Exhibits 10.1 and 10.2. Certain schedules and exhibits are omitted under Item 601(a)(5) of Regulation S-K, and Tenet agrees to furnish them to the SEC upon request.

04—Continue

← View all 8-K filings